Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $446.8 million.

  • Catalyst Pharmaceuticals' Retained Earnings rose 9491.29% to $446.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $446.8 million, marking a year-over-year increase of 9491.29%. This contributed to the annual value of $285.2 million for FY2024, which is 13514.17% up from last year.
  • Catalyst Pharmaceuticals' Retained Earnings amounted to $446.8 million in Q3 2025, which was up 9491.29% from $394.0 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Retained Earnings' 5-year high stood at $446.8 million during Q3 2025, with a 5-year trough of -$46.3 million in Q1 2021.
  • In the last 5 years, Catalyst Pharmaceuticals' Retained Earnings had a median value of $86.4 million in 2023 and averaged $123.6 million.
  • In the last 5 years, Catalyst Pharmaceuticals' Retained Earnings skyrocketed by 5004.2% in 2021 and then surged by 703280.58% in 2023.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Retained Earnings stood at -$26.3 million in 2021, then skyrocketed by 289.52% to $49.9 million in 2022, then soared by 143.22% to $121.3 million in 2023, then surged by 135.14% to $285.2 million in 2024, then skyrocketed by 56.68% to $446.8 million in 2025.
  • Its last three reported values are $446.8 million in Q3 2025, $394.0 million for Q2 2025, and $341.9 million during Q1 2025.